PMID- 24304103
OWN - NLM
STAT- MEDLINE
DCOM- 20140620
LR  - 20211021
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 176
IP  - 2
DP  - 2014 May
TI  - Mycophenolate mofetil in patients with anti-neutrophil cytoplasmic 
      antibody-associated vasculitis: a prospective pharmacokinetics and clinical 
      study.
PG  - 172-9
LID - 10.1111/cei.12246 [doi]
AB  - Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) treatment 
      strategy is based on immunosuppressive agents. Little information is available 
      concerning mycophenolic acid (MPA) and the area under the curve (AUC) in patients 
      treated for AAV. We evaluated the variations in pharmacokinetics for MPA in 
      patients with AAV and the relationship between MPA-AUC and markers of the 
      disease. MPA blood concentrations were measured through the enzyme-multiplied 
      immunotechnique (C(0), C(30), C(1), C(2), C(3), C(4), C(6) and C(9)) to determine 
      the AUC. Eighteen patients were included in the study. The median (range) MPA 
      AUC(0-12) was 50.55 (30.9-105.4) mg/h/l. The highest coefficient of determination 
      between MPA AUC and single concentrations was observed with C(3) (P < 0.0001) and 
      C(2) (P < 0.0001) and with C(4) (P < 0.0005) or C(0) (P < 0.001). Using linear 
      regression, the best estimation of MPA AUC was provided by a model including 
      C(30), C(2) and C(4): AUC = 8.5 + 0.77 C(30) + 4.0 C(2) + 1.7 C(4) (P < 0.0001). 
      Moreover, there was a significant relationship between MPA AUC(0-12) and 
      lymphocyte count (P < 0.01), especially CD19 (P < 0.005), CD8 (P < 0.05) and CD56 
      (P < 0.05). Our results confirm the interindividual variability of MPA AUC in 
      patients treated with MMF in AAV and support a personalized therapy according to 
      blood levels of MPA.
CI  - (c) 2013 British Society for Immunology.
FAU - Chaigne, B
AU  - Chaigne B
AD  - Department of Immunology and Nephrology, Tours University Hospital, Tours, 
      France; Department of Internal Medicine, Tours University Hospital, Tours, 
      France; Universite Francois Rabelais, Tours, France.
FAU - Gatault, P
AU  - Gatault P
FAU - Darrouzain, F
AU  - Darrouzain F
FAU - Barbet, C
AU  - Barbet C
FAU - Degenne, D
AU  - Degenne D
FAU - Francois, M
AU  - Francois M
FAU - Szymanski, P
AU  - Szymanski P
FAU - Rabot, N
AU  - Rabot N
FAU - Golea, G
AU  - Golea G
FAU - Diot, E
AU  - Diot E
FAU - Maillot, F
AU  - Maillot F
FAU - Lebranchu, Y
AU  - Lebranchu Y
FAU - Nivet, H
AU  - Nivet H
FAU - Paintaud, G
AU  - Paintaud G
FAU - Halimi, J-M
AU  - Halimi JM
FAU - Guillevin, L
AU  - Guillevin L
FAU - Buchler, M
AU  - Buchler M
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Enzyme Inhibitors)
RN  - HU9DX48N0T (Mycophenolic Acid)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug 
      therapy/*metabolism
MH  - Area Under Curve
MH  - Enzyme Inhibitors/pharmacokinetics/therapeutic use
MH  - Female
MH  - Humans
MH  - Linear Models
MH  - Lymphocyte Count
MH  - Male
MH  - Middle Aged
MH  - Mycophenolic Acid/*analogs & derivatives/*pharmacokinetics/therapeutic use
MH  - Prospective Studies
PMC - PMC3992029
OTO - NOTNLM
OT  - anti-neutrophil cytoplasmic antibody-associated vasculitis
OT  - mycophenolate mofetil
OT  - pharmacokinetics
EDAT- 2013/12/07 06:00
MHDA- 2014/06/21 06:00
PMCR- 2015/05/01
CRDT- 2013/12/06 06:00
PHST- 2013/11/29 00:00 [accepted]
PHST- 2013/12/06 06:00 [entrez]
PHST- 2013/12/07 06:00 [pubmed]
PHST- 2014/06/21 06:00 [medline]
PHST- 2015/05/01 00:00 [pmc-release]
AID - 10.1111/cei.12246 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2014 May;176(2):172-9. doi: 10.1111/cei.12246.